US firm snaps up Dublin diagnostics gem Biosensia

22nd July, 2018
Niamh O’Luanaigh, chief operating officer, Biosensia

Company: Biosensia

Done Deal: US acquisition

The clincher:“We are very excited about bringing our advanced platform together with Kypha’s specialised biomarker testing and achieving the clinical impact that we designed RapiPlex to fulfil” - Niamh O’Luanaigh, chief operating officer, Biosensia

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Get basic

*New subscribers only

You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Tom Maguire: Tax changes we make now could help business for years

More Business Tom Maguire 10 months ago

The Daily Briefing

The Daily Briefing